CD5 expression in de novo diffuse large B-cell lymphomas by Went, P. et al.
Annals of Oncology 20: 789–798, 2009letters to the editor
CD5 expression in de novo
diffuse large B-cell lymphomas
Ennishi et al. [1] recently described de novo CD5-positive
diffuse large B-cell lymphomas (CD5+ DLBCLs), which are
now recognized in the new 2008 World Health Organization
(WHO) classification of hematopoietic and lymphoid tumors
as an immunohistochemical subgroup of DLBCL not otherwise
specified. We looked for immunohistochemical CD5
expression in a previously well-characterized DLBCL tissue
microarray [2] of patients treated with a combination
chemotherapy with cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) or CHOP-like regimen
without rituximab and found CD5 expression in 10 of 260
tumors (4%). Secondary transformed or preexisting DLBCLs
were excluded.
In our cohort, 82 tumors were classified as primary
extranodal, whereas 178 were nodal DLBCLs. All 10 de novo
CD5+ DLBCLs showed BCL2 expression and eight showed
MUM1/IRF4 expression (Table 1). MUM1/IRF4 indicates the
possibility of a post-germinal-center-cell phenotype. The
transcription factor BCL6 was expressed in 50% of these
tumors; by FISH analysis trisomy 3 as origin of BCL6
deregulation was excluded. Although patients with de novo
CD5+ DLBCL showed a tendency toward higher stages, there
was no correlation of CD5 expression with Ann Arbor stage,
sex, B symptoms, International Prognostic Index, lactate
dehydrogenase or survival. We, therefore, agree with Ennishi
et al. that large-scale prospective studies are required to further
define the relevance of CD5 in DLBCL. In this context, future
studies should address specifically the primary site, as the
separation of primary nodal and extranodal lymphomas is
emphasized by the 2008 WHO classification, which defines new
site-specific large B-cell lymphomas, e.g. DLBCL of the central
nervous system (CNS). Although at times it can be difficult to
discriminate primary nodal from primary extranodal
lymphomas with major nodal involvement, extranodal
lymphomas may not equal to nodal counterparts. This matters
especially in de novo CD5+ DLBCL, as the often CD5+
intravascular large B-cell lymphomas are now recognized as
own subgroup of DLBCL. The concept of site-specific impact
on tumor biology is strikingly challenged in de novo CD5+
DLBCLs: (i) several studies found a relation of prognosis and
CD5 protein expression and (ii) they are often primary
extranodal, but the primary site can be found in various organs.
Of our 10 CD5+ DLBCLs, one was of testicular origin, while
two of four nodal lymphomas showed extranodal involvement.
In the study of Ennishi et al., 45% of the reported cases were
primary extranodal lymphomas. CNS involvement in 13% of
de novo CD5+ DLBCLs has been reported in the large study of
Yamaguchi et al. [3], which is substantially higher than in
conventional DLBCL.
The basis of this association of involvement of extranodal
and immunoprivileged sites and biological behavior in
de novo CD5+ DLBCLs still remains to be elucidated.
Comprehension of physiological CD5+ B-cell homing
properties may help to understand why in these
lymphomas expression of CD5 is of higher relevance than
primary site.
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Table 1. Features of de novo CD5+ diffuse large B-cell lymphoma. Percentages of immunohistochemically positive tumor cells are indicated
Age/sex CD10 (%) BCL2 (%) BCL6 (%) MUM1 (%) Stage FU DOD
1 n.a. 0 100 0 100 n.a. n.a. n.a.
2 79/M 80 90 80 50 n.a. 3 Yes
3 76/F 80 10 80 50 n.a. 72 Yes
4 83/F 0 90 50 30 III 6 No
5 n.a. 0 80 0 40 III 17 Yes
6 79/M 0 90 0 0 n.a. n.a. n.a.
7 81/F 20 90 50 25 III 16 No
8 80/M 0 70 n.a. 35 II 62 No
9 82/F 0 90 10 30 II 11 Yes
10 39/F 0 80 n.a. 0 IV 106 No
FU, follow-up in months; DOD, dead of disease; n.a., not available; M, male; F, female.
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